Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Challenges associated with synthetic lethality in cancer therapeutics

Timothy Yap • 10 Sep 2022
ESMO 2022

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the challenges associated with synthetic lethality in cancer therapeutics, including the development of reliable predictive biomarkers of response and resistance, and identification of which patients will benefit or not benefit from these treatments. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Timothy Yap

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:41
Copanlisib and olaparib in PIK3CA hotspot, PTEN and DDR mutant tumors
Timothy Yap • 7 Apr 2024
2:31
PF-07220060 in HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy
Timothy Yap • 2 Jun 2023
1:24
A phase I/II trial to preliminary efficacy of BNT142 in prospectively confirmed CLDN6+ solid tumors
Timothy Yap • 2 Jun 2023
The content of VJOncology is intended for healthcare professionals